Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...

The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Shares of Bio-Techne Corp. TECH shed 2.13% to $57.44 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.24% to 6,800.26 and Dow ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Ousted Venezuelan President Nicolás Maduro pleaded not guilty to narcotrafficking charges during his arraignment in U.S. federal court Monday, defiantly telling a judge that he was still the head of ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion. "Immediately upon close, this ...

Biotech called the shots in the Bay Area’s year-end capital scramble, with the single largest sale in the region clocking in ...

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet ...